HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT05203341

NBI-1065845 medication research for adults with depression

About this titleRead the official source — NCT05203341

Researchers compared NBI-1065845 and placebo to find out how the approaches affected depression symptoms in adults with depression.

Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

What did researchers investigate?

Researchers compared NBI-1065845 and placebo to find out how the approaches affected depression symptoms in adults with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Birmingham and 40 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: February 21, 2022
Recruitment status
Completed
Enrollment listed in the registry
183
Sponsor
Neurocrine Biosciences
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Bulgaria, Czechia, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT05203341
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 in Adult Subjects With Major Depressive Disorder (MDD)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham, United States · Huntsville, United States · Riverside, United States

37 more locations
  • San Diego, United States
  • San Francisco, United States
  • Torrance, United States
  • Hartford, United States
  • Palmetto Bay, United States
  • Gaithersburg, United States
  • Weldon Spring, United States
  • Columbus, United States
  • North Canton, United States
  • Oklahoma City, United States
  • Memphis, United States
  • Dallas, United States
  • Houston, United States
  • Draper, United States
  • Plovdiv, Bulgaria
  • Rousse, Bulgaria
  • Sofia, Bulgaria
  • Tsarev Brod, Bulgaria
  • Varna, Bulgaria
  • Veliko Tarnovo, Bulgaria
  • Vratsa, Bulgaria
  • Kladno, Czechia
  • Pilsen, Czechia
  • Prague, Czechia
  • Bełchatów, Poland
  • Chełmno, Poland
  • Gdansk, Poland
  • Katowice, Poland
  • Košice, Slovakia
  • Rimavská Sobota, Slovakia
  • Trenčín, Slovakia
  • Vranov nad Topľou, Slovakia
  • Gothenburg, Sweden
  • Halmstad, Sweden
  • Lund, Sweden
  • Stockholm, Sweden
  • Czechia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared NBI-1065845 and placebo to find out how the approaches affected depression symptoms in adults with depression.

Who is behind this study?

The study sponsor is Neurocrine Biosciences, a biotech company.

Did this study involve medication?

Yes. The study involved medication, including Placebo and NBI-1065845.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies